AR095098A1 - Derivado de azol benceno con actividad inhibidora de xantina oxidasa - Google Patents

Derivado de azol benceno con actividad inhibidora de xantina oxidasa

Info

Publication number
AR095098A1
AR095098A1 ARP140100314A ARP140100314A AR095098A1 AR 095098 A1 AR095098 A1 AR 095098A1 AR P140100314 A ARP140100314 A AR P140100314A AR P140100314 A ARP140100314 A AR P140100314A AR 095098 A1 AR095098 A1 AR 095098A1
Authority
AR
Argentina
Prior art keywords
diseases
optionally substituted
hydrogen atom
groups
group optionally
Prior art date
Application number
ARP140100314A
Other languages
English (en)
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of AR095098A1 publication Critical patent/AR095098A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/04Drugs for disorders of the urinary system for urolithiasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Se proporciona un compuesto o una de sus sales aceptables desde el punto de vista farmacéutico o un producto farmacéutico o una composición farmacéutica que contiene el mismo como principio activo, que tiene una excelente actividad inhibidora de xantina oxidasa y es útil como un agente terapéutico o un agente preventivo para enfermedades asociadas con xantina oxidasa tales como gota, hiperuricemia, síndrome de lisis tumoral, cálculos urinarios, hipertensión, dislipidemia, diabetes, enfermedades cardiovasculares tales como ateroesclerosis o insuficiencia cardíaca, enfermedades renales tales como nefropatia diabética, enfermedades respiratorias tales como enfermedades pulmonares obstructivas crónicas, enfermedades de inflamación intestinal o enfermedades autoinmunes. Reivindicación 1: Un compuesto representado por la fórmula (1) o una de sus sales aceptables desde el punto de vista farmacéutico, en donde R¹ representa OR, NRR que puede formar un anillo o SR, en el cual R y R representan en forma independiente un átomo de hidrógeno, un grupo alquilo C₁₋₈ sustituidos en forma opcional con uno o una pluralidad de grupos alcoxi C₁₋₈, átomos de halógeno o grupos hidroxilo, un grupo arilo sustituido en forma opcional con uno o una pluralidad de grupos alquilo C₁₋₈, grupos alcoxi C₁₋₈ o átomos de halógeno, o un grupo heteroarilo sustituido en forma opcional con uno o una pluralidad de grupos alquilo C₁₋₈, grupos alcoxi C₁₋₈ o un átomo de halógeno; R² representa un átomo de hidrógeno o un grupo alquilo C₁₋₈; y X¹, X² y X³; son en forma independiente CR³ o un átomo de nitrógeno, o X¹ es CR³ o un átomo de nitrógeno, y X² y X³ juntos forman un anillo de benceno, en el cual R³ es un átomo de hidrógeno o un grupo alquilo C₁₋₈.
ARP140100314A 2013-01-31 2014-01-30 Derivado de azol benceno con actividad inhibidora de xantina oxidasa AR095098A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013017167 2013-01-31

Publications (1)

Publication Number Publication Date
AR095098A1 true AR095098A1 (es) 2015-09-30

Family

ID=51262388

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100314A AR095098A1 (es) 2013-01-31 2014-01-30 Derivado de azol benceno con actividad inhibidora de xantina oxidasa

Country Status (36)

Country Link
US (1) US9388174B2 (es)
EP (1) EP2952513B1 (es)
JP (1) JP5734532B2 (es)
KR (1) KR102199258B1 (es)
CN (1) CN104968662B (es)
AR (1) AR095098A1 (es)
AU (1) AU2014213396B2 (es)
BR (1) BR112015018033B1 (es)
CA (1) CA2897928C (es)
CL (1) CL2015002117A1 (es)
CY (1) CY1122015T1 (es)
DK (1) DK2952513T3 (es)
ES (1) ES2744817T3 (es)
HK (1) HK1215806A1 (es)
HR (1) HRP20191554T1 (es)
HU (1) HUE047028T2 (es)
IL (2) IL239940B (es)
LT (1) LT2952513T (es)
MA (1) MA38295B1 (es)
ME (1) ME03516B (es)
MX (1) MX364483B (es)
MY (1) MY181731A (es)
NZ (1) NZ709407A (es)
PE (1) PE20151329A1 (es)
PH (2) PH12015501640A1 (es)
PL (1) PL2952513T3 (es)
PT (1) PT2952513T (es)
RS (1) RS59371B1 (es)
RU (1) RU2641891C2 (es)
SA (1) SA515360829B1 (es)
SG (1) SG11201505993PA (es)
SI (1) SI2952513T1 (es)
TW (1) TWI606048B (es)
UA (1) UA117124C2 (es)
WO (1) WO2014119681A1 (es)
ZA (1) ZA201505240B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2953931T1 (sl) 2013-01-31 2017-08-31 Vertex Pharmaceuticals Incorporated Piridon amidi kot modulatorji natrijevih kanalov
LT3080134T (lt) 2013-12-13 2018-11-12 Vertex Pharmaceuticals Incorporated Piridono amidų provaistai, naudotini kaip natrio kanalų moduliatoriai
US20170217948A1 (en) 2014-07-30 2017-08-03 Teijin Pharma Limited Xanthine oxidase inhibitor
NZ729045A (en) * 2014-07-30 2022-05-27 Teijin Pharma Ltd Crystal of azole benzene derivative
SG11201700741WA (en) 2014-07-30 2017-02-27 Teijin Pharma Ltd Azole benzene derivative and crystalline form thereof
JP6732004B2 (ja) 2016-02-19 2020-07-29 国立大学法人鳥取大学 認知症治療薬または予防薬
AU2017364804A1 (en) * 2016-11-28 2019-05-02 Teijin Pharma Limited Therapeutic drug or prophylactic drug for diabetic nephropathy
EP3625214B1 (en) 2017-05-16 2022-07-06 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
EP3752152A1 (en) 2018-02-12 2020-12-23 Vertex Pharmaceuticals Incorporated A method of treating pain
CR20220316A (es) 2019-12-06 2022-10-07 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio
WO2022256622A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU645867B2 (en) * 1990-11-30 1994-01-27 Teijin Pharma Limited 2-arylthiazole derivative and pharmaceutical composition containing the same
ATE270550T1 (de) * 1995-04-07 2004-07-15 Teijin Ltd Wirkstoff zum schutz für organ oder gewebe
NZ307521A (en) * 1995-04-21 1999-04-29 Meiji Seika Kaisha 1-(2-(het)ring-)-(het)ring)-4- or 5-benzimidazole derivates as modulators of the gaba receptor complex
JP2002105067A (ja) 2000-09-28 2002-04-10 Teijin Ltd 2−フェニルチアゾール誘導体、およびそれを有効成分とする医薬組成物
JP5222561B2 (ja) * 2005-10-07 2013-06-26 キッセイ薬品工業株式会社 含窒素芳香族複素環化合物およびそれを含有する医薬組成物
WO2008126770A1 (ja) * 2007-04-05 2008-10-23 Astellas Pharma Inc. トリアリールカルボン酸誘導体の製造方法
US8227500B2 (en) 2007-04-11 2012-07-24 Kissei Pharmaceutical Co., Ltd. 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same
WO2010018458A2 (en) 2008-08-12 2010-02-18 Crystalgenomics, Inc. Phenol derivatives and methods of use thereof
WO2010128163A2 (en) 2009-05-08 2010-11-11 Pike Pharma Gmbh Small molecule inhibitors of influenza a and b virus and respiratory syncytial virus replication
WO2011101867A2 (en) 2010-02-19 2011-08-25 Cadila Healthcare Limited Substantially pure salts of febuxostat and processes for preparation thereof
WO2011139886A2 (en) 2010-04-29 2011-11-10 Dr. Reddy's Laboratories Ltd. Preparation of febuxostat

Also Published As

Publication number Publication date
PH12015501640B1 (en) 2015-10-12
IL259824B (en) 2020-04-30
MX2015009655A (es) 2015-12-07
RU2015132105A (ru) 2017-02-03
RU2641891C2 (ru) 2018-01-23
ZA201505240B (en) 2016-08-31
ME03516B (me) 2020-04-20
IL259824A (en) 2018-07-31
BR112015018033B1 (pt) 2023-02-14
US20150376174A1 (en) 2015-12-31
PL2952513T3 (pl) 2020-01-31
JPWO2014119681A1 (ja) 2017-01-26
SA515360829B1 (ar) 2018-10-11
KR20150112955A (ko) 2015-10-07
IL239940B (en) 2018-07-31
KR102199258B1 (ko) 2021-01-06
HRP20191554T1 (hr) 2019-11-29
JP5734532B2 (ja) 2015-06-17
RS59371B1 (sr) 2019-11-29
BR112015018033A2 (pt) 2017-07-11
CL2015002117A1 (es) 2015-10-30
LT2952513T (lt) 2019-10-25
NZ709407A (en) 2019-09-27
WO2014119681A1 (ja) 2014-08-07
HUE047028T2 (hu) 2020-04-28
TWI606048B (zh) 2017-11-21
CY1122015T1 (el) 2020-10-14
PT2952513T (pt) 2019-09-27
MA38295A1 (fr) 2017-12-29
EP2952513A1 (en) 2015-12-09
ES2744817T3 (es) 2020-02-26
EP2952513B1 (en) 2019-07-10
PH12018500261A1 (en) 2018-09-10
UA117124C2 (uk) 2018-06-25
SG11201505993PA (en) 2015-08-28
SI2952513T1 (sl) 2019-08-30
MA38295B1 (fr) 2018-04-30
AU2014213396A1 (en) 2015-07-23
BR112015018033A8 (pt) 2019-11-05
DK2952513T3 (da) 2019-09-02
AU2014213396B2 (en) 2017-05-11
CN104968662B (zh) 2018-03-30
CA2897928A1 (en) 2014-08-07
PH12015501640A1 (en) 2015-10-12
PH12018500261B1 (en) 2018-09-10
PE20151329A1 (es) 2015-10-12
HK1215806A1 (zh) 2016-09-15
TW201443047A (zh) 2014-11-16
US9388174B2 (en) 2016-07-12
IL239940A0 (en) 2015-08-31
CN104968662A (zh) 2015-10-07
EP2952513A4 (en) 2015-12-09
CA2897928C (en) 2021-02-16
MY181731A (en) 2021-01-05
MX364483B (es) 2019-04-26

Similar Documents

Publication Publication Date Title
AR095098A1 (es) Derivado de azol benceno con actividad inhibidora de xantina oxidasa
PH12017500276A1 (en) Aminopyrimidinyl compounds as jak inhibitors
PH12016500467B1 (en) Aminoheteroarlyl benzamides as kinase inhibitors
PH12016501972A1 (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
BR112015005243A2 (pt) métodos para o tratamento de câncer de mama localmente avançado
DK2970216T3 (da) Biarylamidforbindelser som kinaseinhibitorer
RS54873B1 (sr) Policiklična-karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba
PH12017500416A1 (en) Compounds and compositions as raf kinase inhibitors
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
EA201791289A1 (ru) Ингибиторы клеточного некроза и связанные с ними способы
JP2017505285A5 (es)
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
TR201906325T4 (tr) Tetrazolon sübstitüeli dihidropiridinon MGAT2 inhibitörleri.
EA201692298A1 (ru) Производные карбоксамидов
EA201890532A1 (ru) Новые аннелированные бензамиды
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
UY36124A (es) Derivados de carboxamida
AR101364A1 (es) Derivado de ácido azolcarboxílico
BR112018003335A2 (pt) composições farmacêuticas compreendendo 3-(5-amino-2-metil-4-oxo-4h-quinazolina-3-il)-piperidina-2,6-diona
TH173740B (th) สไพโรไซโคลเฮพเทนเป็นสารยับยั้งของ rock
TH171902B (th) สารประกอบเฮเทอโรไซคลิค
CU20160170A7 (es) Derivados de carboxamida
TH167246B (th) สารประกอบไบแอริลเอไมด์ เป็นสารยับยั้งไคเนส
TH167738B (th) 1h-1, 8-แนพไธริดิน-2-โอนในรูปสารประกอบต้านการเพิ่มจำนวน

Legal Events

Date Code Title Description
FB Suspension of granting procedure